{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:11:32Z","timestamp":1788459092369,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Expression levels of the cell surface glycoprotein, CD7, and the serine protease, elastase 2 (ELA2), in the leukemic cells of patients with chronic myeloid leukemia (CML) have been associated with clinical outcome. However, little is known about the mechanisms that underlie the variable expression of these genes in the leukemic cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      To address this question, we compared the level of their expression with the DNA methylation and histone acetylation status of 5' sequences of both genes in leukemic cell lines and primitive (lin\n                      <jats:sup>-<\/jats:sup>\n                      CD34\n                      <jats:sup>+<\/jats:sup>\n                      ) leukemic cells from chronic phase CML patients. DNA methylation of the\n                      <jats:italic>ELA2<\/jats:italic>\n                      gene promoter did not correlate with its expression pattern in lin\n                      <jats:sup>-<\/jats:sup>\n                      CD34\n                      <jats:sup>+<\/jats:sup>\n                      cells from chronic phase CML patient samples even though there was clear differential DNA methylation of this locus in\n                      <jats:italic>ELA2<\/jats:italic>\n                      -expressing and non-expressing cell lines. In contrast, we found a strong relation between CD7 expression and transcription-permissive chromatin modifications, both at the level of DNA methylation and histone acetylation with evidence of hypomethylation of the\n                      <jats:italic>CD7<\/jats:italic>\n                      promoter region in the lin\n                      <jats:sup>-<\/jats:sup>\n                      CD34\n                      <jats:sup>+<\/jats:sup>\n                      cells from CML patients with high CD7 expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings indicate a link between epigenetic modifications and CD7 expression in primitive CML cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1476-4598-9-41","type":"journal-article","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T02:17:24Z","timestamp":1266891444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia"],"prefix":"10.1186","volume":"9","author":[{"given":"Sally L","family":"Rogers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie J","family":"Eaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixie L","family":"Mager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arefeh","family":"Rouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,22]]},"reference":[{"key":"556_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/306277a0","volume":"306","author":"CR Bartram","year":"1983","unstructured":"Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M: Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983, 306: 277-280. 10.1038\/306277a0","journal-title":"Nature"},{"key":"556_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc2368","volume":"8","author":"M Savona","year":"2008","unstructured":"Savona M, Talpaz M: Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer. 2008, 8: 341-350. 10.1038\/nrc2368","journal-title":"Nat Rev Cancer"},{"key":"556_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973, 243: 290-293. 10.1038\/243290a0","journal-title":"Nature"},{"key":"556_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007, 7: 441-453. 10.1038\/nrc2147","journal-title":"Nat Rev Cancer"},{"key":"556_CR5","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006, 355: 2408-2417. 10.1056\/NEJMoa062867","journal-title":"N Engl J Med"},{"key":"556_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.leukres.2004.06.012","volume":"29","author":"K Usuki","year":"2005","unstructured":"Usuki K, Iijima K, Iki S, Urabe A: CML cytogenetic relapse after cessation of imatinib therapy. Leuk Res. 2005, 29: 237-238. 10.1016\/j.leukres.2004.06.012","journal-title":"Leuk Res"},{"key":"556_CR7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001, 293: 876-880. 10.1126\/science.1062538","journal-title":"Science"},{"key":"556_CR8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam M, Latek RR, Daley GQ: Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003, 112: 831-843. 10.1016\/S0092-8674(03)00190-9","journal-title":"Cell"},{"key":"556_CR9","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","volume":"100","author":"C Roche-Lestienne","year":"2002","unstructured":"Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, Fenaux P, Preudhomme C: Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002, 100: 1014-1018. 10.1182\/blood.V100.3.1014","journal-title":"Blood"},{"key":"556_CR10","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006, 107: 4532-4539. 10.1182\/blood-2005-07-2947","journal-title":"Blood"},{"key":"556_CR11","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X Jiang","year":"2007","unstructured":"Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, Eaves C: Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007, 21: 926-935.","journal-title":"Leukemia"},{"issue":"Suppl 2","key":"556_CR12","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.3816\/CLM.2007.s.005","volume":"7","author":"X Jiang","year":"2007","unstructured":"Jiang X, Smith C, Eaves A, Eaves C: The challenges of targeting chronic myeloid leukemia stem cells. Clin Lymphoma Myeloma. 2007, 7 (Suppl 2): S71-80. 10.3816\/CLM.2007.s.005","journal-title":"Clin Lymphoma Myeloma"},{"key":"556_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","volume":"107","author":"AS Yong","year":"2006","unstructured":"Yong AS, Szydlo RM, Goldman JM, Apperley JF, Melo JV: Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood. 2006, 107: 205-212. 10.1182\/blood-2005-05-2155","journal-title":"Blood"},{"key":"556_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.blre.2005.08.002","volume":"20","author":"KD Mason","year":"2006","unstructured":"Mason KD, Juneja SK, Szer J: The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?. Blood Rev. 2006, 20: 71-82. 10.1016\/j.blre.2005.08.002","journal-title":"Blood Rev"},{"key":"556_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.leukres.2006.06.001","volume":"31","author":"H Chang","year":"2007","unstructured":"Chang H, Yeung J, Brandwein J, Yi QL: CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. Leuk Res. 2007, 31: 157-162. 10.1016\/j.leukres.2006.06.001","journal-title":"Leuk Res"},{"key":"556_CR16","doi-asserted-by":"publisher","first-page":"8215","DOI":"10.1073\/pnas.89.17.8215","volume":"89","author":"M Zimmer","year":"1992","unstructured":"Zimmer M, Medcalf RL, Fink TM, Mattmann C, Lichter P, Jenne DE: Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter. Proc Natl Acad Sci USA. 1992, 89: 8215-8219. 10.1073\/pnas.89.17.8215","journal-title":"Proc Natl Acad Sci USA"},{"key":"556_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/sj.leu.2404488","volume":"21","author":"I Hoebeke","year":"2007","unstructured":"Hoebeke I, De Smedt M, Stolz F, Pike-Overzet K, Staal FJ, Plum J, Leclercq G: T-, B- and NK-lymphoid, but not myeloid cells arise from human CD34(+)CD38(-)CD7(+) common lymphoid progenitors expressing lymphoid-specific genes. Leukemia. 2007, 21: 311-319. 10.1038\/sj.leu.2404488","journal-title":"Leukemia"},{"key":"556_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10428199509051697","volume":"17","author":"A Barcena","year":"1995","unstructured":"Barcena A, Muench MO, Roncarolo MG, Spits H: Tracing the expression of CD7 and other antigens during T- and myeloid-cell differentiation in the human fetal liver and thymus. Leuk Lymphoma. 1995, 17: 1-11. 10.3109\/10428199509051697","journal-title":"Leuk Lymphoma"},{"key":"556_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/417091a","volume":"417","author":"Y Weinrauch","year":"2002","unstructured":"Weinrauch Y, Drujan D, Shapiro SD, Weiss J, Zychlinsky A: Neutrophil elastase targets virulence factors of enterobacteria. Nature. 2002, 417: 91-94. 10.1038\/417091a","journal-title":"Nature"},{"key":"556_CR20","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/blood.V98.9.2645","volume":"98","author":"PJ Ancliff","year":"2001","unstructured":"Ancliff PJ, Gale RE, Liesner R, Hann IM, Linch DC: Mutations in the ELA2 gene encoding neutrophil elastase are present in most patients with sporadic severe congenital neutropenia but only in some patients with the familial form of the disease. Blood. 2001, 98: 2645-2650. 10.1182\/blood.V98.9.2645","journal-title":"Blood"},{"key":"556_CR21","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.4049\/jimmunol.176.5.2991","volume":"176","author":"A Rouhi","year":"2006","unstructured":"Rouhi A, Gagnier L, Takei F, Mager DL: Evidence for epigenetic maintenance of Ly49a monoallelic gene expression. J Immunol. 2006, 176: 2991-2999.","journal-title":"J Immunol"},{"key":"556_CR22","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1182\/blood-2003-11-4026","volume":"103","author":"X Jiang","year":"2004","unstructured":"Jiang X, Zhao Y, Chan WY, Vercauteren S, Pang E, Kennedy S, Nicolini F, Eaves A, Eaves C: Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia. Blood. 2004, 103: 3897-3904. 10.1182\/blood-2003-11-4026","journal-title":"Blood"},{"key":"556_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature02399","volume":"428","author":"J Grimwood","year":"2004","unstructured":"Grimwood J, Gordon LA, Olsen A, Terry A, Schmutz J, Lamerdin J, Hellsten U, Goodstein D, Couronne O, Tran-Gyamfi M: The DNA sequence and biology of human chromosome 19. Nature. 2004, 428: 529-535. 10.1038\/nature02399","journal-title":"Nature"},{"key":"556_CR24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/nature04689","volume":"440","author":"MC Zody","year":"2006","unstructured":"Zody MC, Garber M, Adams DJ, Sharpe T, Harrow J, Lupski JR, Nicholson C, Searle SM, Wilming L, Young SK: DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. Nature. 2006, 440: 1045-1049. 10.1038\/nature04689","journal-title":"Nature"},{"key":"556_CR25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides T: Chromatin modifications and their function. Cell. 2007, 128: 693-705. 10.1016\/j.cell.2007.02.005","journal-title":"Cell"},{"key":"556_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature05919","volume":"447","author":"AP Feinberg","year":"2007","unstructured":"Feinberg AP: Phenotypic plasticity and the epigenetics of human disease. Nature. 2007, 447: 433-440. 10.1038\/nature05919","journal-title":"Nature"},{"key":"556_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrg1748","volume":"7","author":"AP Feinberg","year":"2006","unstructured":"Feinberg AP, Ohlsson R, Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2006, 7: 21-33. 10.1038\/nrg1748","journal-title":"Nat Rev Genet"},{"key":"556_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00335-008-9133-x","volume":"19","author":"A Rouhi","year":"2008","unstructured":"Rouhi A, Mager DL, Humphries RK, Kuchenbauer F: MiRNAs, epigenetics, and cancer. Mamm Genome. 2008, 19: 517-525. 10.1007\/s00335-008-9133-x","journal-title":"Mamm Genome"},{"key":"556_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/301089a0","volume":"301","author":"AP Feinberg","year":"1983","unstructured":"Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983, 301: 89-92. 10.1038\/301089a0","journal-title":"Nature"},{"key":"556_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrc1279","volume":"4","author":"AP Feinberg","year":"2004","unstructured":"Feinberg AP, Tycko B: The history of cancer epigenetics. Nat Rev Cancer. 2004, 4: 143-153. 10.1038\/nrc1279","journal-title":"Nat Rev Cancer"},{"key":"556_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.cell.2005.07.024","volume":"122","author":"TH Bestor","year":"2005","unstructured":"Bestor TH: Transposons reanimated in mice. Cell. 2005, 122: 322-325. 10.1016\/j.cell.2005.07.024","journal-title":"Cell"},{"key":"556_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/BF00286709","volume":"83","author":"V Greger","year":"1989","unstructured":"Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B: Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet. 1989, 83: 155-158. 10.1007\/BF00286709","journal-title":"Hum Genet"},{"key":"556_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrg962","volume":"3","author":"PA Jones","year":"2002","unstructured":"Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3: 415-428. 10.1038\/nrg962","journal-title":"Nat Rev Genet"},{"key":"556_CR34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","volume":"13","author":"MJ Bueno","year":"2008","unstructured":"Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernandez-Piqueras J, Malumbres M: Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008, 13: 496-506. 10.1016\/j.ccr.2008.04.018","journal-title":"Cancer Cell"},{"key":"556_CR35","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/sj.leu.2401486","volume":"13","author":"M Lubbert","year":"1999","unstructured":"Lubbert M, Tobler A, Daskalakis M: Cytosine demethylation of the proteinase-3\/myeloblastin primary granule protease gene during phagocyte development. Leukemia. 1999, 13: 1420-1427. 10.1038\/sj\/leu\/2401486","journal-title":"Leukemia"},{"key":"556_CR36","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1074\/jbc.274.2.1085","volume":"274","author":"I Nuchprayoon","year":"1999","unstructured":"Nuchprayoon I, Shang J, Simkevich CP, Luo M, Rosmarin AG, Friedman AD: An enhancer located between the neutrophil elastase and proteinase 3 promoters is activated by Sp1 and an Ets factor. J Biol Chem. 1999, 274: 1085-1091. 10.1074\/jbc.274.2.1085","journal-title":"J Biol Chem"},{"key":"556_CR37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nsmb.1594","volume":"16","author":"R Straussman","year":"2009","unstructured":"Straussman R, Nejman D, Roberts D, Steinfeld I, Blum B, Benvenisty N, Simon I, Yakhini Z, Cedar H: Developmental programming of CpG island methylation profiles in the human genome. Nat Struct Mol Biol. 2009, 16: 564-571. 10.1038\/nsmb.1594","journal-title":"Nat Struct Mol Biol"},{"key":"556_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/(SICI)1096-8652(199907)61:3<178::AID-AJH4>3.0.CO;2-8","volume":"61","author":"GA Martin-Henao","year":"1999","unstructured":"Martin-Henao GA, Quiroga R, Sureda A, Garcia J: CD7 expression on CD34+ cells from chronic myeloid leukaemia in chronic phase. Am J Hematol. 1999, 61: 178-186. 10.1002\/(SICI)1096-8652(199907)61:3<178::AID-AJH4>3.0.CO;2-8","journal-title":"Am J Hematol"},{"key":"556_CR39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1034\/j.1600-0609.2003.00133.x","volume":"71","author":"AP Normann","year":"2003","unstructured":"Normann AP, Egeland T, Madshus IH, Heim S, Tjonnfjord GE: CD7 expression by CD34+ cells in CML patients, of prognostic significance?. Eur J Haematol. 2003, 71: 266-275. 10.1034\/j.1600-0609.2003.00133.x","journal-title":"Eur J Haematol"},{"key":"556_CR40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1158\/1078-0432.505.11.2","volume":"11","author":"N Kosugi","year":"2005","unstructured":"Kosugi N, Ebihara Y, Nakahata T, Saisho H, Asano S, Tojo A: CD34+CD7+ leukemic progenitor cells may be involved in maintenance and clonal evolution of chronic myeloid leukemia. Clin Cancer Res. 2005, 11: 505-511.","journal-title":"Clin Cancer Res"},{"key":"556_CR41","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/cncr.11223","volume":"97","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S: Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003, 97: 1033-1041. 10.1002\/cncr.11223","journal-title":"Cancer"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-9-41.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T08:44:16Z","timestamp":1685436256000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-9-41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,22]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["556"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-9-41","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,22]]},"assertion":[{"value":"5 October 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"41"}}